Search

—The influence of exposure to mobile phone radiation on in vitro platelet aggregation has been studied. It has been shown that a 30-min exposure of blood samples to mobile phone radio frequency waves increases ADP-induced platelet aggregation in groups of healthy volunteers and patients with stroke, whereas platelet aggregation in JAKV617F-positive patients with polycythemia vera is significantly suppressed and is eventually completely inhibited. The mechanisms that underlie this phenomenon may be associated with cell oxidative stress and anomalies the JAK2 signal transduction pathway in malignized blood cells. The results indicate that it is important to set safety standards for the use of mobile devices by patients with various diseases.

The JAK2 V617F somatic mutation is one of the most frequent markers of CHIP (clonal hematopoiesis of indeterminate potential). CHIP is characterized by the presence of a myeloid cells clone in peripheral blood in the absence of the sufficient reasons to diagnose the hematologic disease. The CHIP is proposed as a potential independent risk factor for vascular pathology. The aim of this study is to identify carriers of JAK2 V617F mutation among patients admitted for planned hospitalization at the Federal Center of Cardiovascular Surgery of Krasnoyarsk.The study included 930 venous blood samples. JAK2 V617F mutation was detected by using the allele - specific real time polymerase chain reaction.JAK2 V617F mutation was detected in 15 (1.6%) patients, but only two of them had blood cell count that could cause a hematological disease to be suspected.The inclusion of the JAK2 V617F mutation detection in the complex of laboratory tests of the cardiovascular patients can facilitate the timely identification of patients with increased thrombotic risk, as well as the timely diagnosis of myeloproliferative diseases.Соматическая мутация V617F в гене JAK2 является одним из наиболее частых маркеров клонального гемопоэза «неопределенного потенциала», так называемого синдрома CHIP (clonal hematopoiesis of indeterminate potential). Синдром CHIP характеризуется наличием в периферической крови клона миелоидных клеток при отсутствии достаточных оснований для диагноза онкогематологического заболевания. Наличие CHIP предложено рассматривать как потенциальный независимый фактор риска сосудистой патологии. Цель работы - выявление мутации V617F в гене JAK2 у пациентов, поступивших на плановую госпитализацию в ФГБУ «Федеральный центр сердечно - сосудистой хирургии» Красноярска. Материалы и методы. В исследование включено 930 образцов венозной крови пациентов. Выявление мутации V617F в гене JAK2 выполняли методом аллель - специфической полимеразной цепной реакции в режиме реального времени. Результаты. Среди обследованного контингента выявлены 15 (1,6%) пациентов с мутацией V617F в гене JAK2, при этом только у двух из них показатели гемограммы могли указать на возможность гематологического заболевания. Заключение. Включение теста выявления мутации V617F гена JAK2 в меню лабораторных исследований пациентов кардиологического профиля может способствовать своевременному выявлению больных с повышенным тромбогенным риском, а также своевременной диагностике миелопролиферативных заболеваний.

Background: Expression of mRNA thrombopoietin receptor (MPL) is detected in various tissues, but peripheral blood cells mature thrombopoietin receptor found in the platelet and mononuclear cells only (http://www.genecards.org/). It has previously been shown MPL mRNA regulates mobilization of bone marrow stem cells (Xiao N. et al., Blood, 2015) and activation of Th2-lymphocytes (Takyar S. et al., J Exp Med, 2013). MPL mRNA expression in bone marrow is associated with the progression of AML (Wetzler M. et al., J Clin Oncol, 1997) and increase of it expression in bone marrow megakaryocytes in Ph- negative myeloproliferative neoplasm (MPN) more pronounced in patients with primary myelofibrosis (PMF) (Bock O. et al., J Pathol, 2004) has been described. MPL mRNA level in venous blood leukocytes in patients with hematologic malignancies is unknown. Aims: Evaluate the MPL mRNA expression in venous blood leukocytes in patients with certain hematologic malignancies Methods: Real-time PCR was performed to detect of MPL mRNA transcripts levels in white blood cells 21 healthy volunteers, 28 patients with chronic myeloid neoplasm (MPN: PMF - 2, PV- 21 and ET - 5), 27 patients with chronic lymphocytic leukemia (CLL), 48 patients with chronic myeloid leukemia (CML), 3 patients with acute lymphocytic leukemia (ALL) and 8 patients with acute myeloid leukemia (AML). Venous blood were collected in tube with RNAse inhibitor. Total RNA was isolated using "Ribo-zol-D" (Aplisens). 10 µg of total RNA were transcribed using "Reverta-L" (Aplisens). PCR was optimized for the thermocycler iQ5 (Bio-Rad) under following condition: 40 cycle of 95 C for 15 sec and 60 C for 60 sec, reaction mixture contained 1X KCl PCR buffer, 2 mM MgCl2, 400 uM dNTP, 300 uM forward and reverse primers, 200 uM probe and 1 unit Taq-polymerase. The results were calculated utilizing the delta Ct method in the software package of "R". The threshold cycles (Ct) MPL gene and housekeeping gene GAPD determined using Cy0 method. The results was normalization with GAPDH reference gene and are presented as median and quartiles (25% and 75%). Results: mRNA MPL expression level in leukocytes venous blood decreased among PMF (0.024, 0.03) > ET (0.013; 0.003-0.016) = PV (0.010; 0.007-0.018) > CML (0.002; 0.0008-0.005) > CLL (0.0005; 0.0002-0.0016) = AML (0.0021; 0.0006-0.0027) = ALL (0.0018; 0.0009-0.0027). MPL mRNA expression level was no correlated with any blood cells count. Summary and Conclusions: Our study support the hypothesis of the independence certain functions mRNA MPL and functions mature thrombopoetin receptor in blood cells. Measurement of mRNA MPL can used as an additional diagnostic marker for the differentiation of MPN and evaluate progress in hematologic malignancies. Figure Expression levels mRNA MPL gene in explored patients groups Figure. Expression levels mRNA MPL gene in explored patients groups Disclosures No relevant conflicts of interest to declare.